Alchem Pharmaceutical firm under scrutiny for collusion regarding Buscopan component.
The Indian drugmaker Alchem has attracted the attention of the European Union's antitrust regulators. These authorities suspect Alchem of being part of a cartel that fixed prices and distributed quotas for the active ingredient in the painkiller Buscopan. The European Commission revealed this news on Thursday, stating that it has received allegations against Alchem.
Allegedly, Alchem and other companies were involved in determining the minimum selling price and dividing up quotas through negotiations. They may have also shared important business information.
The active element being discussed is Butylscopolamin, used for treating abdominal pain and cramps. So far, Alchem has not responded to these accusations. In 2023, the European Commission had already fined the companies Alkaloids of Australia, Alkaloids Corporation, Boehringer, Linnea, and Transo-Pharm a total of 13.4 million euros for their role in manipulating prices of Butylscopolamin, the active ingredient in Buscopan.
Read also:
The Pharmaceutical company Alchem, under investigation for price collusion related to Buscopan's active ingredient, allegedly participated in price agreements and distribution quotas with other companies. If these accusations are proven true, Alchem could face penalties similar to those imposed on Alkaloids of Australia, Alkaloids Corporation, Boehringer, Linnea, and Transo-Pharm in 2023, who were fined for manipulating Butylscopolamin prices, the same active ingredient used in Buscopan.
